VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
UFPTUFP Technologies, Inc.
$259.80$2.0B
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksUFPTFinancials

UFP Technologies, Inc. (UFPT) Financials

30Y historyFree accessUpdated daily

Revenue growth has moderated from 40% levels in 2024 to 4.1% in 2026Q1, while gross margins remain constrained within a tight 27.7% to 30.0% band.

UFPT Income Statement

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08Dec'07Dec'06Dec'05Dec'04Dec'03Dec'02Dec'01Dec'00Dec'99Dec'98Dec'97Dec'96
Sales/Revenue608.85M602.8M504.42M400.07M353.79M206.32M179.37M198.38M190.46M147.84M146.13M138.85M139.31M139.22M130.96M127.24M120.77M99.23M110.03M93.6M93.75M83.96M68.62M60.9M61.19M61.57M74.49M58.8M47.2M45.5M39.4M
Revenue Growth %11.19%19.5%26.08%13.08%71.48%15.02%-9.58%4.16%28.82%1.17%5.24%-0.33%0.06%6.31%2.92%5.36%21.7%-9.82%17.56%-0.16%11.66%22.35%12.68%-0.47%-0.62%-17.34%26.69%24.58%3.74%15.48%15.54%
Cost of Goods Sold436.23M432.39M357.73M287.85M263.53M155.21M134.69M144.42M142.15M112.36M111.48M101.4M102.43M98.57M92.78M91M86.15M72.51M81.47M70.78M74.51M69.36M54.65M50.18M49.08M50.65M53.79M41.6M32.2M31.4M27.9M
COGS % of Revenue-71.73%70.92%71.95%74.49%75.23%75.09%72.8%74.64%76%76.29%73.03%73.53%70.8%70.84%71.52%71.34%73.07%74.04%75.63%79.48%82.61%79.64%82.39%80.22%82.26%72.21%70.75%68.22%69.01%70.81%
Gross Profit172.62M170.41M146.69M112.22M90.26M51.11M44.68M53.96M48.31M35.49M34.65M37.45M36.88M40.65M38.19M36.24M34.62M26.72M28.56M22.81M19.24M14.6M13.97M10.72M12.11M10.92M20.7M17.2M15M14.1M11.5M
Gross Margin %28.35%28.27%29.08%28.05%25.51%24.77%24.91%27.2%25.36%24%23.71%26.97%26.47%29.2%29.16%28.48%28.66%26.93%25.96%24.37%20.52%17.39%20.36%17.61%19.78%17.74%27.79%29.25%31.78%30.99%29.19%
Gross Profit Growth %-16.17%30.71%24.34%76.59%14.39%-17.19%11.7%36.13%2.42%-7.49%1.56%-9.27%6.45%5.35%4.71%29.55%-6.46%25.22%18.57%31.75%4.51%30.28%-11.41%10.8%-47.23%20.36%14.67%6.38%22.61%22.34%
Operating Expenses80.07M78.07M65.8M54.56M34.86M29.9M27.95M29.25M27.76M23.84M24.11M24.01M23.85M23.24M21.53M21.37M20.24M18.54M18.82M15.56M14.18M12.43M12.11M10.83M11.64M13.65M17.32M13.9M11.8M11.1M9.3M
OpEx % of Revenue-12.95%13.04%13.64%9.85%14.49%15.58%14.74%14.57%16.13%16.5%17.29%17.12%16.69%16.44%16.79%16.76%18.68%17.11%16.63%15.13%14.8%17.64%17.78%19.02%22.17%23.25%23.64%25%24.4%23.6%
Selling, General & Admin79.73M77.44M62.22M50.89M45.8M29.48M27.49M29.25M27.76M23.84M24.11M24.01M23.85M23.24M21.53M21.37M20.24M18.54M18.82M15.56M14.18M12.43M12.11M10.83M11.64M13.65M14.24M11.6M9.9M9.3M7.8M
SG&A % of Revenue-12.85%12.33%12.72%12.94%14.29%15.33%14.74%14.57%16.13%16.5%17.29%17.12%16.69%16.44%16.79%16.76%18.68%17.11%16.63%15.13%14.8%17.64%17.78%19.02%22.17%19.11%19.73%20.97%20.44%19.8%
Research & Development0000000010.5M1.1M1.3M1.3M1.4M1.2M1.3M0000000000000000
R&D % of Revenue--------5.51%0.74%0.89%0.94%1%0.86%0.99%----------------
Other Operating Expenses333K633K3.58M3.67M-10.94M416K459K064K-1.1M00312K0-2.06K000000000003.08M2.3M1.9M1.8M1.5M
Operating Income92.55M92.34M80.9M57.66M55.4M21.22M16.73M24.71M19.61M11.69M12.24M11.71M11.56M17.4M16.67M15.72M14.38M8.18M8.42M7.25M5.05M2.17M2.14M-1.51M466K-3.74M3.39M3.3M3.2M3M2.2M
Operating Margin %15.2%15.32%16.04%14.41%15.66%10.28%9.33%12.45%10.3%7.91%8.37%8.44%8.3%12.5%12.73%12.35%11.91%8.24%7.66%7.74%5.39%2.59%3.12%-2.48%0.76%-6.08%4.54%5.61%6.78%6.59%5.58%
Operating Income Growth %-14.14%40.29%4.09%161.1%26.81%-32.28%25.98%67.72%-4.45%4.46%1.32%-33.55%4.39%6.04%9.29%75.8%-2.9%16.25%43.39%132.83%1.23%242.16%-423.7%112.46%-210.51%2.58%3.13%6.67%36.36%100%
EBITDA116.24M115.76M95.61M69.07M67.29M29.63M25M32.88M27.44M17.33M17.87M16.56M15.94M21.48M19.59M18.5M17.53M11.08M11.4M10.06M8.11M5.11M4.64M1.2M3.15M-456.3K6.47M5.6M5.1M4.8M3.7M
EBITDA Margin %19.09%19.2%18.95%17.26%19.02%14.36%13.94%16.57%14.41%11.72%12.23%11.93%11.44%15.43%14.96%14.54%14.52%11.16%10.36%10.75%8.65%6.08%6.76%1.97%5.15%-0.74%8.68%9.52%10.81%10.55%9.39%
EBITDA Growth %11.29%21.08%38.43%2.65%127.1%18.51%-23.97%19.81%58.37%-3.04%7.92%3.91%-25.81%9.63%5.93%5.5%58.31%-2.86%13.31%24.01%58.86%10.13%287.13%-61.99%790.7%-107.06%15.46%9.8%6.25%29.73%54.17%
D&A (Non-Cash Add-back)23.69M23.43M14.71M11.41M11.89M8.41M8.27M8.17M7.83M5.63M5.63M4.85M4.38M4.08M2.93M2.78M3.15M2.9M2.98M2.82M3.06M2.94M2.49M2.71M2.69M3.28M3.08M2.3M1.9M1.8M1.5M
EBIT92.57M92.32M81.09M57.55M55.48M21.24M16.37M24.32M20.65M11.76M12.39M13.45M11.92M17.41M16.66M15.72M14.38M8.18M9.74M7.25M5.05M2.17M1.86M-103.43K466K-2.72M3.39M3.3M3.2M3M2.2M
Net Interest Income-8.73M-9.8M-8.06M-3.65M-2.76M10K-83K-674K-1.27M166K80K27K-108K-205K-90K-26.87K-115.54K-232.75K-334.29K000000000000
Interest Income0000049K0047K216K149K0001690000000000000000
Interest Expense8.73M9.8M8.06M3.65M2.76M39K83K674K1.32M50K69K27K108K205K92K26.87K115.54K221K334.29K000000000000
Other Income/Expense-8.71M-9.82M-7.87M-3.76M-2.68M-13K-449K-1.06M-1.21M166K80K27K204K-205K-137K-27K34.46K618.56K-269.62K-504K-1.05M-1.3M-784.48K-846.62K-843.12K-1.01M-1.38M-500K-500K-700K-500K
Pretax Income83.84M82.51M73.03M53.9M52.72M21.2M16.28M23.65M18.4M11.86M12.32M11.74M11.77M17.19M16.57M15.69M14.43M8.8M8.11M6.74M4.01M867.3K1.36M-2.36M-377.12K-4.75M2M2.8M2.7M2.3M1.7M
Pretax Margin %13.77%13.69%14.48%13.47%14.9%10.28%9.08%11.92%9.66%8.02%8.43%8.46%8.45%12.35%12.66%12.33%11.95%8.87%7.37%7.2%4.28%1.03%1.98%-3.87%-0.62%-7.72%2.69%4.76%5.72%5.05%4.31%
Income Tax15.22M14.2M14.04M8.98M10.93M5.32M2.91M3.9M4.09M2.65M4.35M4.15M4.21M5.92M5.68M4.91M5.02M2.82M2.99M2.58M1.49M208.21K488.67K-839.32K-143.32K-1.71M920.95K1.1M1.1M1M400K
Effective Tax Rate %18.15%17.21%19.23%16.66%20.73%25.08%17.9%16.48%22.24%22.34%35.29%35.33%35.75%34.42%34.26%31.27%34.79%32.02%36.92%38.32%37.26%24.01%35.93%35.64%38.01%35.99%46%39.29%40.74%43.48%23.53%
Net Income68.62M68.31M58.98M44.92M41.79M15.89M13.37M19.75M14.31M9.21M7.97M7.59M7.56M11.28M10.89M10.35M9.25M5.93M5.12M4.16M2.51M659.09K871.26K-1.52M-233.79K-3.04M1.08M1.7M1.6M1.3M1.3M
Net Margin %11.27%11.33%11.69%11.23%11.81%7.7%7.45%9.96%7.51%6.23%5.45%5.47%5.43%8.1%8.32%8.13%7.66%5.97%4.65%4.44%2.68%0.78%1.27%-2.49%-0.38%-4.94%1.45%2.89%3.39%2.86%3.3%
Net Income Growth %8.12%15.82%31.29%7.5%163.06%18.83%-32.31%38.01%55.39%15.56%4.97%0.45%-32.96%3.5%5.3%11.89%55.96%15.89%23.01%65.38%281.57%-24.35%157.48%-548.32%92.32%-381.51%-36.41%6.25%23.08%0%44.44%
Net Income (Continuing)68.62M68.31M58.98M44.92M41.79M15.89M13.37M19.75M14.31M9.21M7.97M7.59M7.56M11.28M10.89M10.78M9.41M5.98M5.16M4.16M2.51M659.09K871.26K-1.52M-233.79K-3.04M1.08M1.7M1.6M1.3M1.3M
Discontinued Operations0000000000000000000000000000000
Minority Interest00000000000-587K000674.25K525.99K470.56K523K583.53K616.16K633.85K433.81K455.43K0000000
EPS (Diluted)8.808.777.585.835.452.091.772.631.931.261.101.051.051.591.551.481.370.940.820.710.450.130.17-0.34-0.05-0.720.250.350.340.270.26
EPS Growth %7.71%15.7%30.02%6.97%160.77%18.08%-32.7%36.27%53.17%14.55%4.76%0%-33.96%2.58%4.73%8.03%45.74%14.63%15.49%57.78%246.15%-23.53%150%-531.97%92.53%-388%-28.57%2.94%25.93%3.85%36.84%
EPS (Basic)-8.877.695.895.522.111.792.661.951.271.111.071.081.651.631.601.501.020.920.780.500.140.19-0.34-0.05-0.720.250.350.350.280.26
Diluted Shares Outstanding7.8M7.8M7.79M7.7M7.66M7.62M7.57M7.52M7.43M7.34M7.28M7.22M7.17M7.11M7.03M7M6.75M6.29M6.26M5.86M5.57M5.26M4.99M4.49M4.34M4.25M4.39M4.9M4.83M4.86M5M
Basic Shares Outstanding7.72M7.71M7.67M7.62M7.56M7.52M7.48M7.42M7.35M7.25M7.19M7.12M7.03M6.82M6.68M6.48M6.16M5.83M5.55M5.31M5.02M4.8M4.62M4.49M4.34M4.23M4.37M4.81M4.68M4.66M4.87M
Dividend Payout Ratio----------------1.14%1.77%2.05%------------

Key Metrics

Growth RegimeDecelerating
ProfitabilityModerate
Balance SheetFortress
Cash FlowRobust
Top Statement Risk

Customer concentration and OEM reliance

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q1)

Revenue Growth Normalizing After Expansion

As indicated by the most recent quarterly filings, UFPT's year-over-year revenue growth has decelerated significantly from the 40% range observed in 2024 to 4.1% in 2026Q1, suggesting that the initial tailwinds from post-pandemic medical device demand and inorganic expansion are now moderating toward a more sustainable baseline.

The sharp decline in growth rates implies that the company is transitioning from a period of rapid, acquisition-fueled scaling to a phase of organic maturation. Investors should monitor whether the current single-digit growth trajectory reflects a saturation of existing medical platforms or a temporary lull in new product launches from key OEM partners.

Structural Margin Stability Amid Volatility

Based on the provided income statement data, UFPT has maintained gross margins within a tight 27.7% to 30.0% band over the last ten quarters, demonstrating a consistent ability to manage input cost fluctuations despite the inherent sensitivity of its petroleum-based raw material supply chain.

This stability suggests that the company possesses sufficient pricing power to offset commodity volatility, likely bolstered by its sole-source status in critical medical components. However, the lack of significant margin expansion despite the shift toward higher-value medical products warrants investigation into whether rising operational costs are absorbing potential gains from the favorable product mix.

Operating Leverage Constrained by SG&A

According to reported financial statements, SG&A expenses have risen from $13.1 million in 2023Q4 to $21.0 million in 2026Q1, which has effectively capped operating margin expansion despite the company's successful pivot toward higher-margin medical applications and increased total revenue volume over the same period.

The scaling of SG&A suggests that the company is investing heavily in the infrastructure required to support its complex, regulated medical business. While this may be necessary for long-term compliance and integration, it currently prevents the operating income from scaling at the same velocity as gross profit, limiting the potential for margin leverage.

Stock-Based Compensation Impacting Earnings

Analysis of the income statement reveals that stock-based compensation has trended upward, reaching $2.7 million in 2026Q1, which represents a non-trivial portion of operating income and suggests that reported EPS may be slightly inflated by the exclusion of these recurring equity-based expenses from cash-based performance metrics.

Investors should be cautious of the dilutive impact and the potential for these costs to grow as the company scales its workforce to support new medical platforms. A normalized view of earnings should account for these recurring charges to better understand the true cash-generating capacity of the underlying business operations.

UFPT — Frequently Asked Questions

Quick answers to the most common questions about buying UFPT stock.

What was UFP Technologies, Inc.'s (UFPT) revenue in 2025?

For fiscal year 2025, UFP Technologies, Inc. (UFPT) reported total revenue of $602.8M. This represents a 1429.9% increase compared to $39.4M in 1996.

Is UFP Technologies, Inc. (UFPT) profitable?

UFP Technologies, Inc. (UFPT) is profitable, generating $68.3M in net income for the fiscal year ending 2025 with a net profit margin of 11.3%.

What is UFP Technologies, Inc.'s operating profit margin?

UFP Technologies, Inc. (UFPT) reported an operating income of $92.3M, resulting in an operating profit margin of 15.3%. This margin reflects the operational efficiency of the business before interest and taxes.

What is UFP Technologies, Inc.'s gross profit and gross margin?

UFP Technologies, Inc. (UFPT) generated $170.4M in gross profit for the year, representing a gross profit margin of 28.3%. This demonstrates the company's core pricing power and production efficiency.